The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04280718
Recruitment Status : Active, not recruiting
First Posted : February 21, 2020
Last Update Posted : August 4, 2023
Sponsor:
Information provided by (Responsible Party):
argenx

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.


Condition or disease Intervention/treatment Phase
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Biological: Efgartigimod PH20 SC Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 226 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Actual Study Start Date : September 18, 2020
Estimated Primary Completion Date : March 1, 2027
Estimated Study Completion Date : March 1, 2027

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: efgartigimod PH20 SC
Patients treated with efgartigimod PH20 SC
 Biological: Efgartigimod PH20 SC
Subcutaneous administration of efgartigimod
Other Name: ARGX-113


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events and serious adverse events [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]

Secondary Outcome Measures :
  1. Change from baseline over time of the adjusted INCAT score [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  2. Change from baseline over time of the MRC Sum score [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  3. Change from baseline over time of I-RODS disability scores [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  4. Change from baseline over time of mean grip strength [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  5. Change from baseline over time of TUG score [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  6. Percentage of patients without clinical deterioration over time, defined by adjusted INCAT deterioration ≥1 point compared to baseline. [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  7. Percentage of patients with titers of binding antibodies towards efgartigimod and the presence of neutralizing antibodies against efgartigimod. [ Time Frame: Up to 51 weeks ]
  8. Efgartigimod serum concentrations [ Time Frame: Up to 51 weeks ]
  9. Changes from baseline over time of serum IgG levels (total) [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  10. Change from baseline over time in EQ-5D-5L [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  11. Change from baseline over time in BPI SF [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  12. Change from baseline over time in TSQM-9 [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  13. Change from baseline over time in RT-FSS [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  14. Change from baseline over time in HADS [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  15. Percentage of patients performing self-administration over time [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]
  16. Percentage of patients with treatment administered by caregiver over time. [ Time Frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to understand the requirements of the trial, provide written informed consent (including consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits) of this trial.

  2. Male or female patient with one of the following options:

    • Have completed the Week-48 visit of Stage B of the ARGX-113-1802 trial and are considered to be eligible for treatment with efgartigimod PH20 SC; or
    • Have deteriorated during Stage B of the ARGX-113-1802 trial and are considered to be eligible for treatment with efgartigimod PH20 SC, or
    • Have been offered the participation in the OLE trial due to early termination of the ARGX-113-1802 trial (because sufficient events for the primary endpoint analysis of the that trial have been reached and it is stopped) and are considered to be eligible for treatment with efgartigimod PH20 SC treatment; or
    • Have completed the Week-48 visit of the previous cycle of the OLE trial and are considered to be eligible to continue with efgartigimod PH20 SC treatment.
  3. Women of childbearing potential who have a negative urine pregnancy test at baseline before IMP administration.
  4. Women of childbearing potential must use an acceptable method of contraception from signing the ICF until the date of the last administration of IMP.

Exclusion Criteria:

  1. Week-48/ED visit in the ARGX-113-1802 trial or the Week-48 visit of the previous OLE participation occurred more than 14 days prior to SD1 of the OLE trial or the start of a new treatment cycle in the OLE trial and more than 21 days since the last dose of IMP.
  2. Pregnant and lactating women and those intending to become pregnant during the trial.
  3. Patients with clinical evidence of other significant serious disease or patients who underwent a recent or have a planned major surgery, or patients who (intend to) use prohibited medications (see protocol) and therapies during the trial, or any other reason which could confound the results of the trial or put the patient at undue risk.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04280718


Locations
Show Show 148 study locations
Sponsors and Collaborators
argenx
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: argenx
ClinicalTrials.gov Identifier: NCT04280718    
Other Study ID Numbers: ARGX-113-1902
2019-003107-35 ( EudraCT Number )
First Posted: February 21, 2020    Key Record Dates
Last Update Posted: August 4, 2023
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Polyneuropathies
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Polyradiculoneuropathy
Autoimmune Diseases of the Nervous System
 Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Chronic Disease
Disease Attributes
Pathologic Processes